Merck (NYSE: MRK) has reached a $356M deal with the departments of Defense and Health and Human Services to further develop and seek regulatory approval MK-7110, the biopharmaceutical firm's investigational drug for hospitalized COVID-19 patients.
Read More »DoD, HHS Sign $375M Procurement Deal for Eli Lilly COVID-19 Drug
Eli Lilly and Co. (NYSE: LLY) has received a potential $375M contract from the departments of Defense and Health and Human Services to initially supply 300K doses of bamlanivimab, an investigational monoclonal antibody drug for COVID-19.
Read More »Trump Admin Picks Abbott for $760M Rapid COVID-19 Test Delivery Contract
The Trump administration has awarded Abbott Laboratories (NYSE: ABT) a potential $760M contract to provide 150M rapid COVID-19 diagnostics tests.
Read More »HHS, DoD Ink $1.5B Deal With Moderna for COVID-19 Vaccine Production
The departments of Health and Human Services and Defense have signed a potential $1.5B agreement with Moderna to produce 100M doses of its COVID-19 vaccine candidate as part of the U.S. government’s Operation Warp Speed.
Read More »Johnson & Johnson Secures $1B in Federal Vaccine Production Funding
Johnson & Johnson (NYSE: JNJ) has received $1B in U.S. government funding for large-scale production of a potential COVID-19 vaccine as part of the White House’s Operation Warp Speed.
Read More »US Gov’t Invests $2.1B to Advance Sanofi-GSK Team’s COVID-19 Vaccine Dev’t; Alex Azar Quoted
The U.S. government has earmarked $2.1B in total funds to support the development and production of a potential COVID-19 vaccine from pharmaceutical companies Sanofi Pasteur and GlaxoSmithKline (NYSE: GSK).
Read More »HHS, DoD Award $2.05B in COVID-19 Vaccine, Treatment Production Contracts; Alex Azar Quoted
The departments of Defense and Health and Human Services awarded contracts worth $2.05B combined to biopharmaceutical companies Novavax and Regeneron to accelerate the manufacture of their respective COVID-19 vaccine and treatment candidates.
Read More »Emergent BioSolutions Books $628M HHS COVID-19 Vaccine Manufacturing Task Order
The Department of Health and Human Services has awarded Gaithersburg, Md.-based biopharmaceutical company Emergent BioSolutions a $628M task order to support the production of potential vaccines for the novel coronavirus through 2021.
Read More »HHS, AstraZeneca Partner to Accelerate COVID-19 Vaccine Dev’t; Alex Azar Quoted
AstraZeneca and the Department of Health and Human Services have signed a potential $1.2B public-private partnership agreement to further develop a recombinant adenovirus vaccine as potential treatment for the novel coronavirus.
Read More »Health Agencies, Biopharmaceutical Firms Form Partnership to Accelerate COVID-19 Vaccine Development
The National Institutes of Health and three other U.S. health agencies have teamed up with the Foundation for the NIH, European Medicines Agency and 16 biopharmaceutical companies to speed up the development of vaccines and treatments for COVID-19. The Accelerating COVID-19 Therapeutic Interventions and Vaccines partnership will work to streamline clinical trials, coordinate regulatory processes and use assets to accelerate response to the coronavirus pandemic and other future health emergencies, NIH said Friday.
Read More »